Ye Da, Qin Zhiquan, Yan Peiyuan, Wang Qunjiang, Qu Jing, Zhou Qihao
Department of Medical Oncology, Cancer Center, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, Zhejiang Province, China.
Medicine (Baltimore). 2025 Jul 25;104(30):e43592. doi: 10.1097/MD.0000000000043592.
Gallbladder cancer (GBC) is a highly aggressive cancer. When treated using standard chemotherapy, the median overall survival is <1 year. Immune checkpoint inhibitors such as pembrolizumab or durvalumab combined with chemotherapy show promise. However, those immune checkpoint inhibitors are very expensive. Tislelizumab may offer a more affordable alternative for advanced GBC.
We report on the case of a 70-year-old patient with GBC who, after experiencing disease progression following standard second-line chemotherapy, was excluded from participating in a clinical trial due to poor performance status.
The patient was diagnosed with stage IVB (TxN2M0) GBC.
He was treated with tislelizumab in combination with oxaliplatin and capecitabine.
The patient had a progression-free survival of 7 months and overall survival of 16 months. The overall overall survival from the onset of the disease was 23 months.
The administration of tislelizumab improved survival in a patient with advanced gallbladder cancer. Tislelizumab emerged as a potential more cost-effective alternative option to pembrolizumab or durvalumab in our treatment strategy. These findings provide the basis for large-scale clinical trials to confirm the efficacy of tislelizumab for GBC.
胆囊癌（GBC）是一种侵袭性很强的癌症。采用标准化疗时，中位总生存期<1年。帕博利珠单抗或度伐利尤单抗等免疫检查点抑制剂联合化疗显示出前景。然而，那些免疫检查点抑制剂非常昂贵。替雷利珠单抗可能为晚期GBC提供更经济实惠的选择。
我们报告了一例70岁的GBC患者，在标准二线化疗后疾病进展，因身体状况差被排除在一项临床试验之外。
该患者被诊断为IVB期（TxN2M0）GBC。
他接受了替雷利珠单抗联合奥沙利铂和卡培他滨的治疗。
患者无进展生存期为7个月，总生存期为16个月。从疾病发作开始的总生存期为23个月。
替雷利珠单抗的给药改善了一名晚期胆囊癌患者的生存期。在我们的治疗策略中，替雷利珠单抗成为一种可能比帕博利珠单抗或度伐利尤单抗更具成本效益的替代选择。这些发现为大规模临床试验提供了依据，以证实替雷利珠单抗对GBC的疗效。
